Interleukins are signaling proteins released by immune cells that coordinate communication between cells during infection, injury, and disease. They regulate immune activation, inflammation, and tissue repair by binding to specific receptors on target cells.
These molecules act as messengers in the immune system. When a pathogen enters the body, immune cells such as macrophages and dendritic cells release interleukins to alert nearby cells. The signals trigger changes in gene expression, leading to cell proliferation, differentiation, or migration. This network ensures a rapid, targeted defense without overwhelming healthy tissue.
There are 38 known human interleukins, each with distinct roles. For example, IL-1 promotes fever and acute inflammation; IL-2 stimulates T-cell growth; IL-6 drives acute-phase protein production. Their actions are tightly regulated-too much or too little can lead to chronic disease or autoimmunity.
Interleukins are secreted by activated immune cells, primarily leukocytes, but also by epithelial and endothelial cells in tissues. Once released, they diffuse through extracellular fluid and bind to specific receptors on the surface of target cells. This binding triggers intracellular signaling cascades involving kinases and transcription factors like STATs (signal transducers and activators of transcription).
The process begins when an interleukin binds to a receptor complex on the target cell membrane. This activates JAK kinases, which phosphorylate STAT proteins. Phosphorylated STATs dimerize and move into the nucleus, where they regulate gene expression. Genes turned on may promote cell division, improve antimicrobial activity, or suppress excessive inflammation.
For example, IL-4 activates STAT6, leading to the differentiation of naïve CD4+ T cells into Th2 cells. These cells then produce more IL-4, amplifying the signal. This loop supports antibody class switching in B cells to IgE, a key step in allergic responses and parasite defense.
Interleukins are grouped by function and cellular origin. Some support pro-inflammatory responses; others resolve inflammation or maintain tolerance. The following table outlines major interleukins and their primary roles:
| Interleukin | Primary Source Cell | Main Function | Associated Condition if Dysregulated |
|---|---|---|---|
| IL-1β | Macrophages, monocytes | Induces fever, activates endothelium, recruits neutrophils | Chronic inflammation, rheumatoid arthritis |
| IL-2 | Activated T cells | Stimulates T-cell proliferation and survival | Autoimmune disorders, graft-versus-host disease |
| IL-4 | Th2 cells, mast cells | Drives IgE production, promotes alternative macrophage activation | Allergies, asthma, fibrosis |
| IL-10 | Regulatory T cells, macrophages | Suppresses inflammation, limits immune activation | Chronic infections, cancer immune evasion |
Each interleukin operates within a network. IL-12, produced by dendritic cells, promotes Th1 differentiation and interferon-gamma release-critical for fighting intracellular pathogens like Mycobacterium tuberculosis. Meanwhile, IL-17 from Th17 cells enhances neutrophil recruitment and barrier defense but contributes to psoriasis when overactive.
Interleukins are often misunderstood as general "immune boosters." They don't simply increase immunity-they modulate it. Overproduction leads to tissue damage; underproduction results in poor pathogen clearance. For example, high levels of IL-6 correlate with severe outcomes in sepsis and COVID-19, while low IL-2 impairs T-cell memory formation.
Another misconception is that interleukins act alone. They function in concert with other cytokines, chemokines, and hormones. IL-4's effect on B cells depends on co-stimulation via CD40 ligand. Without this signal, IL-4 cannot induce class switching to IgE. This interdependence prevents uncontrolled immune activation.
A lesser-known fact: some interleukins have dual roles depending on context. IL-1β induces inflammation during infection but also supports wound healing in tissue repair. Its function shifts based on concentration, timing, and microenvironment. This duality makes therapeutic targeting complex-blocking IL-1β can reduce joint pain in arthritis but impair skin regeneration.
In allergic asthma, exposure to allergens like pollen activates dendritic cells, which present antigens to naïve T cells. These T cells differentiate into Th2 cells under the influence of IL-4 and IL-25. Th2 cells then secrete large amounts of IL-4, which acts on B cells in lymph nodes.
IL-4 causes B cells to switch from producing IgM to IgE antibodies. IgE binds to Fcε receptors on mast cells in the lungs. Upon re-exposure to the same allergen, cross-linking of IgE triggers mast cell degranulation, releasing histamine and leukotrienes. This causes bronchoconstriction, mucus secretion, and airway swelling-classic asthma symptoms.
Targeting IL-4 is a strategy in biologic therapy. Monoclonal antibodies like dupilumab block the IL-4 receptor alpha subunit, inhibiting both IL-4 and IL-13 signaling. Clinical trials show patients treated with dupilumab experience fewer exacerbations and improved lung function. One study reported a 50% reduction in rescue inhaler use among moderate-to-severe asthmatics after 12 weeks of treatment.
In my lab work, we used IL-4 knockout mice to study allergic airway inflammation. Wild-type mice exposed to ovalbumin developed significant eosinophil infiltration and mucus hypersecretion. Knockout mice showed minimal inflammation despite antigen exposure. This confirmed IL-4's central role in initiating the allergic cascade. We later restored IL-4 expression in T cells only, which reinstated the phenotype-proving that T-cell-derived IL-4 is sufficient to drive disease.
Interleukins are not generic immune stimulants. They are precise regulators of immune behavior. Their actions depend on timing, location, concentration, and cellular context. Misinterpreting them as broad activators leads to ineffective or harmful treatments.
For instance, early trials using anti-IL-1β drugs in sepsis failed because blocking the cytokine too early disrupted host defense. Later trials focused on patient stratification-targeting only those with elevated IL-1β levels-showed modest benefit. This highlights the need for precision in immunomodulation.
Understanding what interleukin does requires seeing it as part of a changing system. A single molecule can have multiple effects across different tissues and disease stages. Research continues to map these networks, especially in autoimmune diseases and cancer immunotherapy.
Interleukins are essential components of immune surveillance and homeostasis. Their precise functions make them both targets and tools in modern medicine.